semaglutide trials near me Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous 7.2 mg for obesity SELECT Cardiovascular Trial Information |
Description
Eligibility includes: Adults with obesity (BMI of 30 or higher) Adults with overweight (BMI of 27 or higher) who also have a weight-related condition, such as: High blood pressure Type 2 diabetes Dyslipidemia A medical evaluation is required to determine eligibility and to rule out contraindications
doi: 10.1016/S0140-6736(08)61246-5
It's known for helping patients lose an average of 14.9% of their body weight
Related article : Mounjaro Vs
doi: 10.2337/dc17-0290
01375-3/asset/2a0aa5b3-9fde-4bd7-ad14-b865e6ec5eb5/main.assets/gr2_lrg.jpg)
